{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:41:20Z","timestamp":1790674880098,"version":"4.1.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J of Pharm Policy and Pract"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>There are limited studies on the role of efficient regulatory mechanisms in facilitating greater access to Hepatitis C virus (HCV) treatment. Evidence to support the importance of effective pharmaceutical policies and regulations in improving access to oral viral drugs towards the elimination of HCV is needed. This study aims to explore the adequacy of the implemented pharmaceutical policies and regulations in Egypt and their role to improve the availability and affordability of direct-acting antivirals (DAAs) to achieve universal access to the treatment of HCV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study adopts a qualitative methodology using desk review of regulatory and legislative information, literature review, and semi-structured interviews with key experts from the concerned governmental regulatory agencies, pharmaceutical industries, academic organizations, professional associations, civil society organizations, and clinicians who are working in researching treatments for hepatitis C.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>The common DAAs available in the market are Daclatasvir, Sofosbuvir, and Sofosbuvir-based direct-acting antiviral combinations. Fast-track medicines registration pathway for marketing authorization of DAAs is used to reduce market access time frames. The pricing policies are supplemented using price negotiation to set up affordable prices that led to a reasonable price for DAAs. Using Trade-Related Aspects of Intellectual Property Rights (TRIPs) flexibility and local production of quality generics DAAs at lower prices. In addition, political will and collaboration between the government, civil society, and pharmaceutical companies improved patients' access to affordable DAAs and succeeding hepatitis C treatment in Egypt.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study findings indicated that the implemented pharmaceutical policies and regulations have an immense role in enhancing access to medicines towards the elimination of hepatitis C in Egypt.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s40545-021-00389-6","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T10:02:55Z","timestamp":1639648975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt\u2014case study"],"prefix":"10.1080","volume":"14","author":[{"given":"Mahmoud H.","family":"Teaima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7259-7577","authenticated-orcid":false,"given":"Adi","family":"Al-Nuseirat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Abouhussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama A.","family":"Badary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"El-Nabarawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"issue":"4","key":"389_CR1","first-page":"214","volume":"13","author":"KR Bhamidimarri","year":"2017","unstructured":"Bhamidimarri KR, Satapathy SK, Martin P. Hepatitis C virus and liver transplantation. Gastroenterol Hepatol (N Y). 2017;13(4):214\u201320.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"389_CR2","unstructured":"World Health Organization (WHO). Hepatitis C fact sheet. Updated 27 July 2020. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 9 Apr 2021."},{"issue":"1","key":"389_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/liv.13186","volume":"37","author":"A Kandeel","year":"2017","unstructured":"Kandeel A, Genedy M, El-Refai S, Funk AL, Fontanet A, Talaat M. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37(1):45\u201353.","journal-title":"Liver Int"},{"issue":"1","key":"389_CR4","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s41598-017-17936-4","volume":"8","author":"SP Kouyoumjian","year":"2018","unstructured":"Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8(1):1661.","journal-title":"Sci Rep"},{"key":"389_CR5","unstructured":"Egypt\u2019s Viral Hepatitis Program. Burden and response: an economic analysis 2017. The World Bank\u2019s. http:\/\/documents.worldbank.org\/curated\/en\/972381517328583384\/pdf\/123066-WP-PUBLIC-P157533-Burden-and-response-An-Economic-Analysis.pdf. Accessed 9 Apr 2021."},{"key":"389_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12913-016-1503-6","volume":"16","author":"SM Tsai","year":"2016","unstructured":"Tsai SM, Kao JT, Tsai YF. How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study. BMC Health Serv Res. 2016;16:247.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"389_CR7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000500963","volume":"35","author":"L Sandmann","year":"2019","unstructured":"Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of chronic hepatitis C: efficacy, side effects and complications. Visc Med. 2019;35(3):161\u201370.","journal-title":"Visc Med"},{"issue":"10179","key":"389_CR8","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/S0140-6736(18)32326-2","volume":"393","author":"JA Holmes","year":"2019","unstructured":"Holmes JA, Rutledge SM, Chung RT. Direct-acting antiviral treatment for hepatitis C. Lancet. 2019;393(10179):1392\u20134.","journal-title":"Lancet"},{"issue":"4","key":"389_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","volume":"15","author":"M Bourli\u00e8re","year":"2015","unstructured":"Bourli\u00e8re M, Bronowicki JP, de Ledinghen V, H\u00e9zode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397\u2013404.","journal-title":"Lancet Infect Dis"},{"key":"389_CR10","unstructured":"Arab Republic of Egypt, Official Gazette. Law No. 151 of 2019 for establishing the Egyptian Drug Authority. https:\/\/manshurat.org\/node\/61255. Accessed 9 Apr 2021."},{"key":"389_CR11","unstructured":"Egyptian Drug Authority. Pharmacy Law 127 for 1955. [Online]. http:\/\/www.eda.mohp.gov.eg\/Files\/95_Pharmacy_law.pdf. Accessed 9 Apr 2021."},{"key":"389_CR12","unstructured":"State of information service. https:\/\/www.sis.gov.eg\/section\/0\/4496?lang=en-us. Accessed 9 Apr 2021."},{"issue":"44","key":"389_CR13","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.3748\/wjg.v24.i44.4959","volume":"24","author":"Y Waheed","year":"2018","unstructured":"Waheed Y, Siddiq M, Jamil Z, Najmi MH. Hepatitis elimination by 2030: progress and challenges. World J Gastroenterol. 2018;24(44):4959\u201361.","journal-title":"World J Gastroenterol"},{"key":"389_CR14","unstructured":"Global Health Sector Strategy on Viral Hepatitis, 2016\u20132021. Geneva: World Health Organization; 2015. https:\/\/www.who.int\/hepatitis\/strategy2016-2021\/ghss-hep\/en\/. Accessed 9 Apr 2021."},{"issue":"10","key":"389_CR15","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.sapharm.2020.02.005","volume":"16","author":"MEK Amin","year":"2020","unstructured":"Amin MEK, N\u00f8rgaard LS, Cavaco AM, Witry MJ, Hillman L, Cernasev A, et al. Establishing trustworthiness and authenticity in qualitative pharmacy research. Res Soc Adm Pharm. 2020;16(10):1472\u201382.","journal-title":"Res Soc Adm Pharm"},{"issue":"5","key":"389_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","volume":"42","author":"LA Palinkas","year":"2015","unstructured":"Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Policy Ment Health. 2015;42(5):533\u201344.","journal-title":"Adm Policy Ment Health"},{"key":"389_CR17","volume-title":"Designing and conducting mixed method research","author":"JW Cresswell","year":"2011","unstructured":"Cresswell JW, Plano Clark VL. Designing and conducting mixed method research. 2nd ed. Thousand Oaks: Sage; 2011.","edition":"2nd"},{"key":"389_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-12169-7","volume-title":"Pharmaceutical prices in the 21st century","author":"H Wanis","year":"2015","unstructured":"Wanis H. Chapter 4\u2014pharmaceutical pricing in Egypt. In: Zaheer-Ud-Din B, editor. Pharmaceutical prices in the 21st century. Cham: Springer; 2015. https:\/\/doi.org\/10.1007\/978-3-319-12169-7."},{"key":"389_CR19","unstructured":"Egyptian Pricing Decree no499\/2012. Egyptian Drug Authority. In Arabic at http:\/\/www.eda.mohp.gov.eg\/Files\/474_499.pdf. Accessed 9 Apr 2021."},{"issue":"5","key":"389_CR20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/liv.14022","volume":"39","author":"SA Lashen","year":"2019","unstructured":"Lashen SA, Shamseya MM, Madkour MA, Aboufarrag GA. Tolerability and effectiveness of generic direct-acting antiviral drugs in eradication of hepatitis C genotype 4 among Egyptian patients. Liver Int. 2019;39(5):835\u201343.","journal-title":"Liver Int"},{"key":"389_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijid.2018.07.025","volume":"75","author":"M Abozeid","year":"2018","unstructured":"Abozeid M, Alsebaey A, Abdelsameea E, Othman W, Elhelbawy M, Rgab A, et al. High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C. Int J Infect Dis. 2018;75:109\u201314.","journal-title":"Int J Infect Dis"},{"issue":"6","key":"389_CR22","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40290-017-0210-x","volume":"31","author":"M Ndomondo-Sigonda","year":"2017","unstructured":"Ndomondo-Sigonda M, Miot J, Naidoo S, Dodoo A, Kaale E. Medicines regulation in Africa: current state and opportunities. Pharm Med. 2017;31(6):383\u201397.","journal-title":"Pharm Med"},{"key":"389_CR23","unstructured":"US Food and Drug Administration (FDA). Learn about FDA, its mission, history, how it's organized, and more. https:\/\/www.fda.gov\/. Accessed 9 Apr 2021."},{"key":"389_CR24","unstructured":"European Medicines Agency. The European Medicines Agency\u2019s contribution to science, medicines and health in 2019. https:\/\/www.ema.europa.eu\/en\/documents\/annual-report\/2019-annual-report-european-medicines-agency_en.pdf. Accessed 9 Apr 2021."},{"key":"389_CR25","unstructured":"Egyptian Drug Authority. Ministry Decree 425\/2015. [Online]. http:\/\/www.eda.mohp.gov.eg\/Files\/766_425_2015.pdf. Accessed 9 Apr 2021."},{"key":"389_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","volume":"142","author":"G Li","year":"2017","unstructured":"Li G, De Clercq E. Current therapy for chronic hepatitis C: the role of direct-acting antivirals. Antivir Res. 2017;142:83\u2013122.","journal-title":"Antivir Res"},{"key":"389_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/IJGM.S127689","volume":"10","author":"NJ Burstow","year":"2017","unstructured":"Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, et al. Hepatitis C treatment: where are we now? Int J Gen Med. 2017;10:39\u201352.","journal-title":"Int J Gen Med"},{"issue":"4","key":"389_CR28","first-page":"256","volume":"40","author":"D Gritsenko","year":"2015","unstructured":"Gritsenko D, Hughes G. Ledipasvir\/sofosbuvir (Harvoni): improving options for hepatitis C virus infection. Pharm Ther. 2015;40(4):256\u201376.","journal-title":"Pharm Ther"},{"issue":"2","key":"389_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s40265-014-0179-7","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs. 2014;74(2):273\u201382.","journal-title":"Drugs"},{"issue":"12","key":"389_CR30","first-page":"751","volume":"41","author":"M Montgomery","year":"2016","unstructured":"Montgomery M, Ho N, Chung E, Marzella N. Daclatasvir (Daklinza): a treatment option for chronic hepatitis C infection. P T. 2016;41(12):751\u20135.","journal-title":"P T"},{"key":"389_CR31","unstructured":"Raedler LA. Once-a-day Harvoni (ledipasvir plus sofosbuvir), a new oral combination for the treatment of patients with genotype 1 chronic hepatitis C infection. Am Health Drug Benefits. 2015;8(Spec Feature):54\u20138."},{"issue":"16","key":"389_CR32","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483\u201393.","journal-title":"N Engl J Med"},{"key":"389_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12876-015-0320-4","volume":"15","author":"S Zhang","year":"2015","unstructured":"Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol. 2015;15:98.","journal-title":"BMC Gastroenterol"},{"key":"389_CR34","unstructured":"Egyptian Initiative for Personal Rights. HCV treatment in Egypt: why cost remains a challenge? November 2014. https:\/\/www.eipr.org\/sites\/default\/files\/pressreleases\/pdf\/hcv_treatment_in_egypt.pdf. Accessed 9 Apr 2021."},{"issue":"1","key":"389_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2055-6640(20)30691-9","volume":"2","author":"A Hill","year":"2016","unstructured":"Hill A, Simmons B, Gotham D, Fortunak J. Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C. J Virus Erad. 2016;2(1):28\u201331.","journal-title":"J Virus Erad"},{"issue":"5","key":"389_CR36","doi-asserted-by":"publisher","first-page":"e1002032","DOI":"10.1371\/journal.pmed.1002032","volume":"13","author":"S Iyengar","year":"2016","unstructured":"Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.","journal-title":"PLoS Med"},{"key":"389_CR37","unstructured":"World Bank. World Bank list of economies (June 2020). https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519. Accessed 9 Apr 2021."},{"key":"389_CR38","unstructured":"Arab Republic of Egypt, Egyptian Drug Authority. http:\/\/196.46.22.218\/EDASearch\/SearchRegDrugs.aspx. Accessed 9 Apr 2021."},{"key":"389_CR39","unstructured":"Hashemite Kingdom of Jordan. Jordan Food and Drug Administration. http:\/\/jfda.jo\/Pages\/viewpage.aspx?pageID=184. Accessed 9 Apr 2021."},{"key":"389_CR40","unstructured":"Republic of Lebanon, Ministry of Public Health. https:\/\/moph.gov.lb\/en\/Pages\/3\/3101\/drugs-public-price-list-. Accessed 9 Apr 2021."},{"key":"389_CR41","unstructured":"Kingdom of Morocco, Ministry of Health. https:\/\/www.sante.gov.ma\/sites\/Ar\/medicaments\/Pages\/PMed.aspx. Accessed 9 Apr 2021."},{"key":"389_CR42","unstructured":"Kingdom of Saudi Arabia, Saudi Food and Drug Authority. https:\/\/www.sfda.gov.sa\/en\/drug\/search\/Pages\/default.aspx. Accessed 9 Apr 2021."},{"key":"389_CR43","unstructured":"United Arab Emirates, Ministry of Health and Prevention. https:\/\/www.mohap.gov.ae\/en\/services\/request-for-a-price-list-of-registered-medications. Accessed 9 Apr 2021."},{"issue":"4","key":"389_CR44","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1108\/JOPP-15-04-2015-B004","volume":"15","author":"L Abdellatif","year":"2015","unstructured":"Abdellatif L, Zaky M. Characteristics of private markets and accessibility of small and medium enterprises to public procurement markets: pharmaceuticals in Egypt. J Public Procure. 2015;15(4):476\u2013513.","journal-title":"J Public Procure"},{"key":"389_CR45","volume-title":"Health care systems and policies. Health services research","author":"CA Gericke","year":"2018","unstructured":"Gericke CA, Britain K, Elmahdawy M, Elsisi G. Health system in Egypt. In: van Ginneken E, Busse R, editors. Health care systems and policies. Health services research. New York: Springer; 2018."},{"key":"389_CR46","unstructured":"Arab Republic of Egypt. 2002. Law 82\/2002 on the protection of intellectual property rights. Official Gazette (22), 2 June 2002. http:\/\/www.wto.org\/english\/thewto_e\/minist_e\/min01_e\/mindecl_trips_e.htm. Accessed 9 Apr 2021."},{"key":"389_CR47","unstructured":"World Intellectual Property Organization. Agreement between the Egyptian Academy of Scientific Research and Technology and the International Bureau of the World Intellectual Property Organization in relation to the functioning of the Egyptian Patent Office as an International Searching Authority and International Preliminary Examining Authority under the Patent Cooperation Treaty. https:\/\/www.wipo.int\/export\/sites\/www\/pct\/en\/texts\/agreements\/ag_eg.pdf. Accessed 9 Apr 2021."},{"key":"389_CR48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1257\/jep.27.1.3","volume":"27","author":"M Boldrin","year":"2013","unstructured":"Boldrin M, Levine DK. The case against patents. J Econ Perspect. 2013;27:3\u201322.","journal-title":"J Econ Perspect"},{"key":"389_CR49","doi-asserted-by":"crossref","unstructured":"'t Hoen E, Passarelli CA. The role of intellectual property rights in treatment access: challenges and solutions. Curr Opin HIV AIDS. 2013;8(1):70\u20134.","DOI":"10.1097\/COH.0b013e32835b6e5a"},{"key":"389_CR50","unstructured":"Egypt Pharmaceuticals & Healthcare Report, 2019. https:\/\/nations-emergentes.org\/wp-content\/uploads\/2019\/02\/egypt-pharmaceutical-survey.pdf. Accessed 9 Apr 2021."},{"key":"389_CR51","doi-asserted-by":"crossref","unstructured":"Egyptian Drug Authority. Ministry Decree 539\/2007. [Online]. http:\/\/www.eda.mohp.gov.eg\/Files\/105_Minister_Decree_539_Both.pdf. Accessed 9 Apr 2021.","DOI":"10.1002\/9780470373699.speced0500"},{"issue":"7","key":"389_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fmed.2020.00457","volume":"19","author":"AK Broojerdi","year":"2020","unstructured":"Broojerdi AK, Sillo HB, Dehaghi RO, Ward M, Refaat M, Parry J. The World Health Organization global benchmarking tool an instrument to strengthen medical products regulation and promote universal health coverage. Front Med. 2020;19(7):457.","journal-title":"Front Med"}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40545-021-00389-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40545-021-00389-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40545-021-00389-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T10:54:00Z","timestamp":1704279240000},"score":1,"resource":{"primary":{"URL":"https:\/\/joppp.biomedcentral.com\/articles\/10.1186\/s40545-021-00389-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1186\/s40545-021-00389-6","relation":{},"ISSN":["2052-3211"],"issn-type":[{"value":"2052-3211","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"11 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}